本研究使用CVM方法估計腸病毒疫苗71型價值，透過支付卡詢價法，對中壢與平鎮地區600位目前正就讀幼稚園孩童的父母進行問卷訪問，進而得知受訪者對於腸病毒疫苗的偏好。估計方式使用OLS方法探討民眾對於願付價值的影響因素，並估計願付價值平均值；使用chow’s test 探討問卷設計的不同是否對估計結果產生差異；使用Tobit 模式探討民眾對於不同預防程度願付價值的差距來源；最後，應用願付價值的估計結果推算孩童統計生命價值。
實證結果顯示，在OLS估計下，腸病毒知識、家中6歲以下孩童數、家中最小孩童年齡及感染經驗等變數與願付價值具有顯著負向關係；所得、疾病預防程度及小孩健康程度變數與願付價值具顯著正向關係。根據chow’s test的檢定結果，證明本研究的估計結果並未因問卷的差異而影響估計結果。平均願付價值預測值，若為一劑高預防性疫苗預測值為3448至3515元；一劑低預防性疫苗的預測值則為2231元；若為五劑高預防性疫苗的預測值為1204至1372元；五劑低預防性疫苗願付價值則為973元。願付價值最高的疫苗為一劑高預防性疫苗。
在Tobit模式估計下，所得水準較高、女性、小孩健康程度較差的受訪者，願意支付較高金額購買疫苗，且相較於低預防性疫苗，將願意支付更高價格購買高預防性疫苗；並且研究結果發現民眾對於不同預防程度疫苗的願付價值存在差異。最後，推算孩童統計生命價值的估計值為0.4至1.08百萬美元。

The purpose of this study is to estimate the value of Enterovirus 71 vaccine by contingent valuation method. We interview 600 parents who have the kids studying in kindergarten and live in Chungli and Pingchen areas to figure out their preference about Enterovirus 71. By using the payment card method, we discuss the factors that determine the respondents’ willingness to pay from the ordinary least square estimation. We also use the Chow’s test to check whether different type of questionnaire changes the parameter estimates. Furthermore, the differences of respondents’ WTP between high-prevention vaccine and low-prevention vaccine are discussed. Finally, we calculate the value of statistics life of kid through willingness to pay of vaccine.
The empirical result show that Enterovirus knowledge, kids under 6 years of age in the family, the youngest kid’s age and disease experience are negative to WTP; income, disease prevention level and health level are positive to WTP. The result of chow’s test shows that different type of questionnaire won’t change the result. The predicted mean value ranges from 3,448 to 3,515 NT dollars in one high-prevention vaccine; it is about 2,231 NT dollars in one low-prevention vaccine; about 1,204 to 1,372 NT dollars in five-dose high-prevention vaccine; and about 973 NT dollars in five-dose low-prevention vaccine. The empirical result in Tobit model also reveal that respondents who are high income, female, with an unhealthy kid will pay more to buy vaccine, and will pay higher amounts to buy high-prevention vaccine than low-prevention vaccine. Eventually, the predicted VSL is $0.4 to 1.08 million dollars.

一、中文文獻
傅祖壇、葉寶文，「應用CVM在健康效益的評估─高血壓疾病預防之願付價格」，
經濟論文叢刊，33：1,1-32頁，2005。
吳正男，「腸病毒71型之病毒特性與感染機制研究及應用」，國防醫學院生命科
學研究所，博士論文，民國91年。
張鑾英，「腸病毒71型臨床、重症危險因子、致病機轉及流行病學研究」，長庚
大學臨床醫學研究，博士論文，民國90年。
夏紹軒，「腸病毒戰爭」，臺北：未來，民國91年。
李秉穎，「腸病毒震撼：社會大眾與醫護人員應有的認知和省思」，臺北：流遠，
民國89年。
湯谷清(計畫主持)，「2007生物技術產業年鑑」，臺北：生物技術開發中心，民
國96年
湯谷清(計畫主持)，「2008生物技術產業年鑑」，臺北：生物技術開發中心，民
國97年。
郭明裕，「臺灣的腸病毒71型風暴」，2008。
(http://www.dryahoo.org.tw/%A6%B8%BA%F4%AD%B6/%BA%F4%B8%F4%A7G%A7i%C4%E6/%C2%E5%C0%F8%A4%E5%B3%B9/%BBO%C6W%AA%BA%B8z%AFf%ACr71%AB%AC%AD%B7%BC%C9.htm)
劉清泉，「臺灣疫苗接種現況」，2005。
(http://www.ncku.edu.tw/~clpharm/YHKYang/vaccine-2007-0117.pdf)
許毓真，「臺灣疫苗大熱潮」，ITIS智網，2007。
(http://www.itis.org.tw/index.jsp)
陳麗敏，「全球疫苗市場分析」，ITIS智網，2006。
(http://www.itis.org.tw/index.jsp)
林青青，「全球疫苗供應不求? ─從疫苗產業特色談起」，華文生技網，2005。
(http://www.bioweb.com.tw/index.asp)
林青青，「全球疫苗市場概況」，華文生技網，2005。
(http://www.bioweb.com.tw/index.asp)
衛生署疾病管制局
(http://www.cdc.gov.tw/mp.asp?mp=1)
台灣疫苗推動協會
(http://www.tivs.com.tw/)
李慶雲兒童感染暨疫苗發展醫藥文教基金會
(http://www.cylfoundation.org.tw/)
二、英文文獻
Alberini, Anna, Alistair Hunt, and Anil Markandya. 2006. “Willingness to Pay to Reduce Mortality Risks: Evidence from a Three-Country Contingent Valuation Study” Environmental & Resource Economics, 33: 251–64.
Alberini, Anna, and Aline Chiabai. 2007. “Urban Environmental Health and Sensitive Populations: How Much are The Italians Willing to Pay to Reduce Their Risks?” Regional Science and Urban Economics, 37: 239–58.
Canh, Do Gia, Dale Whittington, Le Thi Kim Thoa, Nugroho Utomo, Nguyen Thai Hoa, Christine Poulos, Dang Thi Dieu THUY., Dohyeong Kim, Andrew Nyamete, and Camilo Acosta. 2006. “Household Demand for Typhoid Fever Vaccines in Hue, Vietnam” Health Policy and Planning Advance Access, 21(1): 241-55.
Corso, Phaedra S., James K. Hammitt, and John D. Graham. (2001). “Valuing Mortality-Risk Reduction: Using Visual Aids to Improve The Validity of Contingent Valuation”, Journal of Risk and Uncertainty, 23(2): 165–84.
Fonta, William M., H. Eme Ichoju, Kanayo K. Ogujiuba, and Jude O. Chukwu. 2007. “Using a Contingent Valuation Approach for Improved Solid Waste Management Facility: Evidence from Enugu State, Nigeria” Journal of African Economies, 17(2): 277-304.
Gibson, John, Sandra Brans, Michael Cameron, Steven Lim, Frank Scrimgeour, and John Tressler. 2007, “The Value of Statistical Life and The Economics of Landmine Clearance in Developing Countries” World Development, 35(3): 512–31.
Hammitt, James K. 2000. “Evaluating Contingent Valuation of Environmental Health Risks: The Proportionality Test” Association of Environmental and Resource Economists, 20(1): 14– 19.
Hammitt, James K., Jin-Tan Liu and Jin-Long Liu. 2001. “Contingent Valuation of a Taiwanese Wetland” Environment and Development Economics, 6: 259–68.
Kim, Doheyeong, Do G. Canh, Christine Poulos, Le T. K. Thoa, Joe Cook, Nguyen T. Hoa, Andrew Nyamete, Dang T. D. Thuy, Jacqueline Deen, John Clemens, Vu D. Thiem, Dand D. Anh and Dale Whittington. 2008 “Private Demand for Cholera Vaccines in Hue, Vietnam” Value in Health 11(1), 119-28.
Kniesner, Thomas J., and W.Kip Viscusi. 2005. “Value of a Statistical Life: Relative Position vs. Relative Age” Relative Income and Public Policy, 95(2): 142–46.
Luchini, Stephane, Christel Protiere, and Jean- Paul Moatti. 2003. “Eliciting Several Willingness to Pay in a Single Contingent Valuation Survey: Application to Health Care” Health Econ, 12: 51–64.
Liu, Jin-Tan, James K. Hammitt, Jung-Der Wang, and Meng-Wen Tsou. 2005. “Valuation of the Risk of SARS in Taiwan” Health Econ, 14: 83–91.
Liu, Jin-Tan, James K. Hammitt and Jin-Long Liu. 1997. “Estimated hedonic wage function and value of life in a developing country” Economics Letters,57: 353–58.
Parra, Salvador, Fernando J. Aguilar and Javier Calatrava. 2008. “Decision Modelling for Environmental Protection: The Contingent Valuation Method Applied to Greenhouse Waste Management” Biosystems Engineering, 99: 469–77.
Ridder, Annemieke De, and Diana De Graeve. 2005. “Order Bias in Estimates of Willingness to Pay for Drugs to Treat Attention-Deficit/Hyperactivity Disorder” Eur J Health Econom, 6: 146-51.
Jenkins, Robin R., Nicole Owens and Lanelle B. Wiggins. 2001. “Valuing Reduced Risks to Children: The Case of Bicycle Safety Helmets” Contemporary Economic Policy, 19(4): 397–408
Sadri, Hamid, Linda D. Mackeigan, Lawrence A. Leiter, and Thomas R. Einarson. 2005. “Willingness to Pay for Inhaled Insulin: A Contingent Valuation Approach” Pharmacoeconomics, 23(12): 1215–27.
Shiell, Alan, and Lisa Gold. 2003. “If the Price is Right: Vagueness and Values Clarification in Contingent Valuation” Health Econ, 12: 909–19.
Suraratdecha, Chutima, Mattha Ainsworth, Viroj Tangcharoensathien and Dale Whittington. 2005. “The Private Demand for an AIDS Vaccine in Thailand” Health Policy, 71: 271-87.
Tseng, Wei-Chun, and Chi-Chung Chen. 2008. “Valuing The Potential Economic Impact of Climate Change on The Taiwan Trout” Ecological Economics , 65: 282–91.
Viscusi, W.Kip. 1993. “The Value of Risks to Life and Health” Journal of Economic Literature, 31(4): 1912– 46.
Wang, Hua, and Dale Whittington. 2005. “Measuring Individuals’ Valuation Distributions Using a Stochastic Payment Card Approach” Ecological Economics, 55: 143–54.
Yasunaga, Hideo. 2008. “Willingness to Pay for Mass Screening for Prostate Cancer: A Contingent Valuation Survey” International Journal of Urology, 15: 102–5.